Could erlotinib treatment lead to acute cardiovascular events in patients with lung adenocarcinoma after chemotherapy failure?

Erlotinib, an epidermal growth factor receptor and tyrosine kinase inhibitor, is a targeted drug that was approved for the treatment of non-small-cell lung cancers and pancreatic cancers. Targeted tyrosine kinase inhibitors are known to have cardiotoxic effects. However, erlotinib does not have a st...

Descripción completa

Detalles Bibliográficos
Autores principales: Kus, Tulay, Aktas, Gokmen, Sevinc, Alper, Kalender, Mehmet Emin, Camci, Celaletdin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485179/
https://www.ncbi.nlm.nih.gov/pubmed/26150726
http://dx.doi.org/10.2147/OTT.S84480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485179/
https://www.ncbi.nlm.nih.gov/pubmed/26150726
http://dx.doi.org/10.2147/OTT.S84480

Ejemplares similares